These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36222016)

  • 21. The burden of emergency department use for sickle-cell disease: an analysis of the national emergency department sample database.
    Lanzkron S; Carroll CP; Haywood C
    Am J Hematol; 2010 Oct; 85(10):797-9. PubMed ID: 20730795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence, Mortality, and Access to Care for Chronic Kidney Disease in Medicaid-Enrolled Adults With Sickle Cell Disease in California: Retrospective Cohort Study.
    Valle J; Lebensburger JD; Garimella PS; Gopal S
    JMIR Public Health Surveill; 2024 Jul; 10():e57290. PubMed ID: 39008353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data.
    Pisc J; Ting A; Skornicki M; Sinno O; Lee E
    J Comp Eff Res; 2024 Jan; 13(1):e230108. PubMed ID: 38099519
    [No Abstract]   [Full Text] [Related]  

  • 24. Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study.
    Reaven NL; Funk SE; Montouris GD; Saurer TB; Story TJ
    Epilepsy Behav; 2018 Nov; 88():66-73. PubMed ID: 30241056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease.
    Johnson KM; Jiao B; Bender MA; Ramsey SD; Devine B; Basu A
    PLoS One; 2022; 17(4):e0267448. PubMed ID: 35482721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
    Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
    Health Qual Life Outcomes; 2019 Oct; 17(1):155. PubMed ID: 31619251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The direct medical costs of Huntington's disease by stage. A retrospective commercial and Medicaid claims data analysis.
    Divino V; Dekoven M; Warner JH; Giuliano J; Anderson KE; Langbehn D; Lee WC
    J Med Econ; 2013 Aug; 16(8):1043-50. PubMed ID: 23789925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Qualitative Analysis of State Medicaid Coverage Benefits for Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Patients with Sickle Cell Disease (SCD).
    Mupfudze TG; Preussler JM; Sees JA; SanCartier M; Arnold SD; Devine S
    Transplant Cell Ther; 2021 Apr; 27(4):345-351. PubMed ID: 33836889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost of health care for children and adults with sickle cell disease.
    Kauf TL; Coates TD; Huazhi L; Mody-Patel N; Hartzema AG
    Am J Hematol; 2009 Jun; 84(6):323-7. PubMed ID: 19358302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The economic burden of systemic lupus erythematosus in commercially- and medicaid-insured populations in the United States.
    Clarke AE; Yazdany J; Kabadi SM; Durden E; Winer I; Griffing K; Costenbader KH
    Semin Arthritis Rheum; 2020 Aug; 50(4):759-768. PubMed ID: 32531505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors influencing utilization of hospital services by adult sickle cell disease patients: a systematic review.
    Benenson I; Jadotte Y; Echevarria M
    JBI Database System Rev Implement Rep; 2017 Mar; 15(3):765-808. PubMed ID: 28267033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.
    Stein EM; Bonifacio G; Latrémouille-Viau D; Shi S; Guérin A; Wu EQ; Sadek I; Cao X
    J Med Econ; 2021; 24(1):234-243. PubMed ID: 33472483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High Healthcare Utilization in Adolescents with Sickle Cell Disease Prior to Transition to Adult Care: A Retrospective Study.
    Kanter J; Bhor M; Li X; Li FY; Paulose J
    J Health Econ Outcomes Res; 2019; 6(3):174-184. PubMed ID: 32685589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The economic burden of fragile x syndrome: healthcare resource utilization in the United States.
    Sacco P; Capkun-Niggli G; Zhang X; Jose R
    Am Health Drug Benefits; 2013 Mar; 6(2):73-83. PubMed ID: 24991348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence and cost of sickle cell disease in France: real-world analysis using data from the Echantillon Généraliste des Bénéficiaires.
    Beillat M; Durand-Zaleski I; Pirenne F; Bénard S; Chillotti L; Galacteros F
    Front Public Health; 2023; 11():1215605. PubMed ID: 37808997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease.
    Kang HA; Barner JC; Lawson KA; Rascati K; Mignacca RC
    Am J Hematol; 2023 Jan; 98(1):90-101. PubMed ID: 36251408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States.
    Jain SS; Li SS; Xie J; Sutton MB; Fine JT; Edelberg JM; Gao W; Spertus JA; Cohen DJ
    J Med Econ; 2021; 24(1):1115-1123. PubMed ID: 34493144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing super-utilizers and lower-utilizers among commercial- and Medicare-insured adults with sickle cell disease.
    MacEwan SR; Chiang C; O'Brien SH; Creary S; Lin CJ; Hyer JM; Cronin RM
    Blood Adv; 2024 Jan; 8(1):224-233. PubMed ID: 37991988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sickle cell disease complications: Prevalence and resource utilization.
    Shah N; Bhor M; Xie L; Paulose J; Yuce H
    PLoS One; 2019; 14(7):e0214355. PubMed ID: 31276525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of comorbidities associated with sickle cell disease among non-elderly individuals with commercial insurance-A retrospective cohort study.
    Ramsey SD; Bender MA; Li L; Johnson KM; Jiao B; Devine B; Basu A
    PLoS One; 2022; 17(11):e0278137. PubMed ID: 36445914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.